Update 3:10pm: Adds analyst comment. Regeneron (NASDAQ:REGN) won a permanent injunction that blocks drugmakers including, ...

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...

Mylan has paid $96.5 million to settle claims it delayed launching a generic of narcolepsy drug Provigil in exchange for a payment from the originator, Cephalon. Reuters reported the settlement ...

Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug. Cheaper competition to off-patent Advair has been ...

Pfizer (PFL) announced it is spinning off its off-patent drug business and combining it with Real Money Stock of the Day Mylan (MYL) to create a new company. Cramer says that he's keeping an eye ...

Well, that was fast. It took Gov. Jim Justice all of one day after winning a seat in the U.S. Senate to play an exclusive game of political nepotism, appointing his wife, Cathy, to a nine-year term on ...

If you have been diagnosed with moderate to severe chronic Shift Work Sleep Disorder (SWSD) and non-drug therapies have been unsuitable or unsuccessful, MODAFINIL MYLAN may be prescribed to keep ...

This leaflet answers some common questions about RABEPRAZOLE MYLAN. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.

The pharmaceutical company Mylan has been in the hot seat with members ... half the list price of the branded drug. Manchin did also give off all the signs of a proud father, telling Bloomberg ...

The consolidated amended complaint unveiled Tuesday also takes the unprecedented step of going after senior executives at two generic drug companies. Mylan President Rajiv Malik and Emcure ...

Pharmaceutical company Viatris (VTRS 13.52%) reported third-quarter 2024 financial results on Thursday, Nov. 7, that topped ...